Virpax Pharmaceuticals, Inc. (VRPX) News

Virpax Pharmaceuticals, Inc. (VRPX): $1.70

0.03 (+1.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRPX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 422

in industry

Filter VRPX News Items

VRPX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VRPX News Highlights

  • For VRPX, its 30 day story count is now at 2.
  • Over the past 5 days, the trend for VRPX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about VRPX are CNS.

Latest VRPX News From Around the Web

Below are the latest news stories about Virpax Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRPX as an investment opportunity.

News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19

BERWYN, Pa., February 15, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, has been featured in several news outlets discussing potential solutions for two pressing issues: the opioid epidemic and the COVID pandemic.

Yahoo | February 15, 2022

Virpax Reports Favorable Preclinical Safety Data for Envelta™  for the Treatment of Acute and Chronic Pain

BERWYN, Pa., February 10, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, reported promising results from preclinical dose range finding studies for Envelta (NES100), Virpax’s endogenous enkephalin intranasal spray for acute and chronic pain, including pain associated with cancer. These findings complement previous p

Yahoo | February 10, 2022

Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee

LAVAL, Quebec, January 21, 2022--Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. ("Virpax") (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film.

Yahoo | January 21, 2022

Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™

BERWYN, Pa., January 18, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders, and anti-viral indications, reported positive results of four preclinical dermal safety studies for Epoladerm™ (diclofenac epolamine). Epoladerm is an investigational product candidate for the management of pain associated with osteoarthritis of the knee. From these recently concluded animal studies, r

Yahoo | January 18, 2022

Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

BERWYN, Pa., January 04, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax"), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10th through Thursday, January 13th starting at 7:00 a.m. ET. Anthony Mack, Chairman & CEO of Virpax, will be giving the presentation. Management will also be hosting virtual one-on-one meetings on Monday, J

Yahoo | January 4, 2022

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

BERWYN, Pa., December 28, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below.

Yahoo | December 28, 2021

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

BERWYN, Pa., December 20, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., a leading clinical trial services company, for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee. The study will take place in Canada with a CTA filing and en

Yahoo | December 20, 2021

Now Is A Good Time To Buy Virpax Pharmaceuticals Inc. (NASDAQ: VRPX)

During the last session, Virpax Pharmaceuticals Inc. (NASDAQ:VRPX)s traded shares were 0.54 million. At the end of the trading day, the stocks price was $3.68, reflecting an intraday loss of -2.13% or -$0.08. The 52-week high for the VRPX share is $36.00, that puts it down -878.26 from that peak though still a striking 7.88% Now Is A Good Time To Buy Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) Read More »

Marketing Sentinel | December 18, 2021

Virpax reports positive non-human study results for topical spray film that treats chronic pain

Virpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management. Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee. According to a news release, the company reported positive results following the completion of a toxicology and [] The post Virpax reports positive non-human study results for topical spray film that treats chronic pain appeared first on Drug Delivery Business .

Drug Delivery Business | December 8, 2021

Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

BERWYN, Pa., December 08, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, reported positive results following the completion of a toxicology and pharmacokinetic study designed to support clinical trials with Epoladerm™, one of its lead investigational product candidates for the management of pain associated with osteoarthritis of the knee.

Yahoo | December 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4201 seconds.